PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
49.00%
EBIT growth above 1.5x RVPH's 5.85%. David Dodd would confirm if core operations or niche positioning yield superior profitability.
-9.04%
Negative operating income growth while RVPH is at 7.11%. Joel Greenblatt would press for urgent turnaround measures.
48.96%
Net income growth above 1.5x RVPH's 5.90%. David Dodd would check if a unique moat or cost structure secures superior bottom-line gains.
53.59%
EPS growth above 1.5x RVPH's 7.69%. David Dodd would review if superior product economics or effective buybacks drive the outperformance.
51.99%
Diluted EPS growth above 1.5x RVPH's 7.69%. David Dodd would see if there's a robust moat protecting these shareholder gains.
10.21%
Share count expansion well above RVPH's 2.47%. Michael Burry would question if management is raising capital unnecessarily or is over-incentivizing employees with stock.
6.42%
Diluted share count expanding well above RVPH's 2.47%. Michael Burry would fear significant dilution to existing owners' stakes.
No Data
No Data available this quarter, please select a different quarter.
-59.54%
Negative OCF growth while RVPH is at 38.83%. Joel Greenblatt would demand a turnaround plan focusing on real cash generation.
-60.23%
Negative FCF growth while RVPH is at 38.83%. Joel Greenblatt would demand improved cost control or more strategic capex discipline.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-7534.43%
Negative 10Y OCF/share CAGR while RVPH stands at 0.00%. Joel Greenblatt would scrutinize managerial effectiveness and product competitiveness.
-15675.30%
Negative 5Y OCF/share CAGR while RVPH is at 21.52%. Joel Greenblatt would question the firm’s operational model or cost structure.
-5709.37%
Negative 3Y OCF/share CAGR while RVPH stands at 53.59%. Joel Greenblatt would demand an urgent turnaround in the firm’s cost or revenue drivers.
-6744.35%
Both face negative decade-long net income/share CAGR. Martin Whitman would suspect a shrinking or highly disrupted sector.
-20067.21%
Negative 5Y net income/share CAGR while RVPH is 60.51%. Joel Greenblatt would see fundamental missteps limiting profitability vs. the competitor.
-6838.40%
Negative 3Y CAGR while RVPH is 58.01%. Joel Greenblatt might call for a short-term turnaround strategy or cost realignment.
No Data
No Data available this quarter, please select a different quarter.
530.49%
Equity/share CAGR of 530.49% while RVPH is zero. Bruce Berkowitz might see a minor advantage that could compound if the firm maintains positive net worth growth.
431.75%
Positive short-term equity growth while RVPH is negative. John Neff sees a strong advantage in near-term net worth buildup.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-29.38%
Negative asset growth while RVPH invests at 64.40%. Joel Greenblatt checks if the competitor might capture more market share unless our returns remain higher.
-71.36%
We have a declining book value while RVPH shows 89.95%. Joel Greenblatt sees a fundamental disadvantage in net worth creation vs. the competitor.
-100.00%
Both reduce debt yoy. Martin Whitman sees a broader sector shift to safer balance sheets or less growth impetus.
52.82%
We increase R&D while RVPH cuts. John Neff sees a short-term profit drag but a potential lead in future innovations.
-14.04%
Both reduce SG&A yoy. Martin Whitman sees a cost war or cyclical slowdown forcing overhead cuts.